
Drug trial targets stubborn cholesterol
The clinical trial ‘BROADWAY’ tested a once-daily oral medication called Obicetrapib, and found it significantly lowered both LDL cholesterol and lipoprotein(a), two key contributors to cardiovascular disease. The BROADWAY phase 3 trial results were ...


